Evofem Biosciences, Inc. (EVFM)
OTCMKTS: EVFM · Delayed Price · USD
0.0139
-0.0001 (-0.71%)
May 1, 2024, 3:56 PM EDT - Market closed
Evofem Biosciences Revenue
Evofem Biosciences had revenue of $13.56M in the twelve months ending September 30, 2023, down -32.96% year-over-year. Revenue in the quarter ending September 30, 2023 was $5.11M, a -19.76% decrease year-over-year. In the year 2022, Evofem Biosciences had annual revenue of $16.84M with 104.23% growth.
Revenue (ttm)
$13.56M
Revenue Growth
-32.96%
P/S Ratio
0.22
Revenue / Employee
$366,486
Employees
37
Market Cap
3.00M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 16.84M | 8.59M | 104.23% |
Dec 31, 2021 | 8.24M | 7.80M | 1,748.43% |
Dec 31, 2020 | 446.00K | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 0 | - | - |
Dec 31, 2016 | 0 | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Dec 31, 2012 | 100.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 371.62B |
Johnson & Johnson | 85.16B |
Merck & Co. | 60.12B |
AbbVie | 54.32B |
Novartis AG | 49.92B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.86B |
Abbott Laboratories | 40.11B |
EVFM News
- 13 days ago - Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO - PRNewsWire
- 5 weeks ago - Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 - PRNewsWire
- 7 weeks ago - For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy - PRNewsWire
- 3 months ago - Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023 - PRNewsWire
- 4 months ago - EVOFEM BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Evofem Biosciences, Inc. - EVFM - Business Wire
- 5 months ago - Shareholder Alert: Ademi LLP investigates whether Evofem Biosciences, Inc. has obtained a Fair Price in its transaction with Aditxt - PRNewsWire
- 6 months ago - Evofem Biosciences Announces Financial Results for the Third Quarter of 2023 - PRNewsWire
- 7 months ago - Evofem to Participate in the Virtual Investor Ask the CEO Conference - PRNewsWire